Loading stock data…
$17.08-0.28 (-1.61%)
Relay Therapeutics, Inc.
Relay Therapeutics, Inc. in the Healthcare sector is trading at $17.07 with a market capitalization of $4.2B. Wall Street consensus targets $27.58 (12 analysts), implying a +61.6% move over the next 12 months. The stock is currently 20% below its 52-week high of $21.27, remaining 18.6% above its 200-day moving average. On fundamentals, Piotroski 4/9 shows mixed financial quality, Altman Z in the safe zone. The Whystock Score of 100/100 reflects bullish alignment across trend, valuation and analyst targets.
| Metric (USD) | Q2 2026 | Q1 2026 | Q4 2025 | Q3 2025 | Q2 2025 |
|---|---|---|---|---|---|
| Total Revenue | $350,000↓ | $3.00M↓ | $7.00M | $0↓ | $677,000 |
| Gross Profit | — | — | — | — | — |
| Operating Income | -$90.82M↓ | -$78.59M↓ | -$60.63M↑ | -$80.39M↓ | -$76.85M |
| Net Income | -$83.71M↓ | -$73.29M↓ | -$54.89M↑ | -$74.15M↓ | -$70.38M |
Relay Therapeutics, Inc. operates as a clinical-stage precision medicines company. It transforms the drug discovery process with a focus on enhancing small molecule therapeutic discovery in targeted oncology and genetic disease indications. The compa...